Periosteal osteosarcoma - A European review of outcome

Robert J. Grimer*, Stefan Bielack, Silke Flege, Stephen R. Cannon, Gunnar Foleras, Ivan Andreeff, Todor Sokolov, Antonie Taminiau, Martin Dominkus, Mikel San-Julian, Yehuda Kollender, Georg Gosheger

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

89 Scopus citations


Periosteal osteosarcoma is a rare primary malignant bone tumour. Treatment is by surgical excision, but controversy remains about the value of chemotherapy. The members of the European Musculo Skeletal Oncology Society (EMSOS) collaborated to produce a dataset of 119 patients. The predominant site for the tumour was the femur, followed by the tibia. All but 2 patients underwent surgery, with 9 requiring amputation and the others having limb salvage. A total of 81 patients had chemotherapy, of whom 50 had neoadjuvant chemotherapy. There was no standard chemotherapy regime, but all patients receiving chemotherapy were given doxorubicin combined with at least one other agent. The overall survival was 89% at 5 years and 83% at 10 years. Eight patients developed local recurrence, of whom 5 died. Survival was related to appearance of local recurrence (P < 0.0001) but no other single factor. The use of chemotherapy was not shown to be a prognostic factor, but was used in two-thirds of the patients in this study.

Original languageEnglish
Pages (from-to)2806-2811
Number of pages6
JournalEuropean Journal of Cancer
Issue number18
StatePublished - Dec 2005
Externally publishedYes


  • Chemotherapy
  • Local recurrence
  • Outcome
  • Periosteal osteosarcoma


Dive into the research topics of 'Periosteal osteosarcoma - A European review of outcome'. Together they form a unique fingerprint.

Cite this